Brief: Ono Pharmaceutical enters into license agreement with Bristol-Myers Squibb for Prostaglandin E2 receptor antagonists

ONO PHARMACEUTICAL

14/12/2017 01:55

Dec 14 (Reuters) - Ono Pharmaceutical Co Ltd  4528.T   
     
    * Says it entered into license agreement with Bristol-Myers 
Squibb 
Company (BMS)for Prostaglandin E2 receptor antagonists relating 
to Immuno-Oncology programs  
    * Under the terms of this agreement, BMS is granted the 
rights to 
develop and commercialize ONO-4578 and other compounds from PGE2 
receptor antagonist programs worldwide, except Japan, South 
Korea, Taiwan, China and Association of South-East Asian Nations 
(ASEAN)countries 
    * In accordance with this agreement, ONO receives an upfront 
payment of $40 million from BMS 
    * ONO will also receive subsequent clinical, regulatory and 
sales-based milestone payments, as well as royalties based on 
sales of the products in the countries where ONO granted BMS the 
rights for development and commercialization 
 
     
    Source text in Japanese:https://goo.gl/R5ZgX8 
    Further company coverage: 4528.T  
 
 (Beijing Headline News) 
 ((Beijing.HeadlineNews@thomsonreuters.com; +8601082555111; 
Reuters Messaging: Pingping.Li1@thomsonreuters.com@reuters.net))